GCP
AEGR

GSA Capital Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

GSA Capital Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,436
Closed -$205K – 2069
2014
Q1 		$205K Buy
+4,436
New +$260K 0.01% 1376
2013
Q4 		– Sell
-6,442
Closed -$552K – 1872
2013
Q3 		$552K Sell
6,442
-3,103
-33% -$263K 0.04% 723
2013
Q2 		$605K Buy
+9,545
New +$507K 0.07% 442

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GSA Capital Partners's AEGR Position: Q2 2014 in Review

GSA Capital Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2014, closing a stake of 4,436 shares — an estimated $205K sold.

GSA Capital Partners first reported a position in AEGR in Q2 2013 and held it in 3 quarters. The position peaked at $605K in Q2 2013. 129 funds tracked by Wall St. Rank hold AEGR as of Q2 2014.

  • GSA Capital Partners reported no remaining Aegerion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • GSA Capital Partners sold 4,436 Aegerion Pharmaceuticals shares in Q2 2014, an estimated $205K.
  • GSA Capital Partners first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • GSA Capital Partners's Aegerion Pharmaceuticals position peaked at $605K in Q2 2013.
  • 129 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2014.

Based on GSA Capital Partners's 13F filing for Q2 2014, filed 8 Aug 2014.